Industry leaders to take startups to new heights

Asceneuron SA, a clinical stage company dedicated to targeting the root causes of neurodegenerative diseases, is developing orally bioavailable therapeutics for debilitating neurodegenerative disorders, including Alzheimer’s Disease and Parkinson’s Disease, as well as orphan tauopathies.  The appointment of Barbara Angehrn Pavik as the new Chief Executive Officer (CEO) is part of a leadership transition poised to propel the company into its next phase of growth, with two compounds in clinical development. Angehrn Pavik is an industry stalwart with more than 20 years of experience who has held key leadership roles in EU and US companies, including Amgen, Onyx, Exelixis, and was the Founder and CEO of Stepstone Pharma. Most recently, as the Chief Business Officer at Vifor, Angehrn Pavik played a key role in the company's acquisition by CSL Limited.

Ymmunobio appoints new Chief Financial Officer (CFO)
Christian Germa has assumed the role of Chief financial Officer at Ymmunobio, the preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments present a large market potential and broad applicability in solid tumors. Ymmunobio is making extensive progress in developing antibodies that have an influence on the immune system by reinstating its immune response to cancers or directly inhibiting cancer cell proliferation. Germa brings over 25 years of finance and board experience to support the startup on their next journey. He spent several years as a non-executive director at Faively Transport before taking on the same position at Onset SA from France. He spent the past seven years at GTT also as a non-executive director.

Marry Jane welcomes Chief Revenue officer and CFO
Zug bases startup Marry Jane is a leading European producer in the cannabis industry and operator of Europe's largest indoor cannabis cultivation, with a vertical integration from cultivation to production to retail and with distribution and subsidiaries in Western and Eastern Europe. The company primarily produces and sells CBD products such as CBD flowers, hashish, bottled CBD drops, terpene sprays, sports gels, e-liquids, GMP-certified isolate, and other products that are sold to wholesalers and retailers around the world. With Hendrik de Jong as Chief Revenue Officer and Dr. Ralf Stanovsky as the company's new Chief Financial Officer, the company is ready to go to new heights.  Prior to Marry Jane, Hendrik worked at FMCG company Mars Inc, a global, family-owned company, where he was a general manager of the last four years as general manager of Mars' Austrian Mars' Austrian multicategory business for the past four years, after 16 years of experience in senior positions at Haribo and Coca-Cola.

Ralf Stanovsky is a versatile global leader and strategic finance manager with more than 20 years of experience in Europe, Asia, the Middle East and the Americas. Prior to joining MJ, he built and developed the financial strategy for a renewable energy start-up. He started his career at Roland Berger Strategy Consultants and held several senior management positions in the past at companies such as Deutsche Lufthansa AG and SIXT SE.

(Press release/RAN)